Summary of Madrigal Pharmaceuticals Q3 2025 Earnings Call

1Key Financial Results and Metrics

Net Sales: $287.3 million for Q3 2025, representing a 35% increase quarter-over-quarter.

Patient Growth: Over 29,500 patients are currently on Rezdiffra, up from 23,000 in Q2 2025.

Prescriber Base: More than 10,000 healthcare providers have prescribed Rezdiffra.

Gross to Net Management: Anticipated to be in the midpoint of the 20% to 30% range for Q4 2025, with expectations to rise to the high 30% range in 2026.

R&D Expenses: Increased to $174 million, primarily due to a one-time $117 million expense for licensing an oral GLP-1.

SG&A Expenses: Rose to $209.1 million, reflecting increased commercial investment for Rezdiffra.

2Strategic Updates and Business Highlights

Rezdiffra Launch: Positioned as one of the most successful specialty launches, with annualized sales exceeding $1 billion within six months.

Payer Strategy: Progressing well with 2026 payer contracting aimed at broad first-line access without step edits.

Pipeline Development: Advancing the Phase III MAESTRO-NASH outcomes trial for compensated MASH cirrhosis (F4c) and exploring additional pipeline assets, including a new oral GLP-1 (MGL-2086).

Global Expansion: Launched Rezdiffra in Germany, with plans for a country-by-country approach in Europe.

3Forward Guidance and Outlook

2026 Expectations: Robust net sales growth anticipated, with continued patient additions and favorable payer agreements expected to enhance access.

Market Penetration: Less than 10% of the target market is currently treated, indicating significant growth potential.

Long-Term Strategy: Focus on building a durable pipeline and maintaining leadership in the MASH market, with patent protection for Rezdiffra extending to 2045.

4Bad News, Challenges, or Points of Concern

Increased Expenses: Significant rise in R&D and SG&A expenses due to ongoing investments and licensing agreements.

Market Competition: The entry of competitors like Novo's GLP-1s may impact market dynamics and patient access, although the company believes this will ultimately increase awareness and diagnosis of MASH.

Payer Coverage Variability: Some payers, such as Aetna, have opted not to include Rezdiffra on their formulary for 2026, which may limit access through prior authorization processes.

5Notable Q&A Insights

Real-World Evidence: Positive anecdotal feedback from prescribers regarding Rezdiffra's efficacy and adherence rates, with some reports suggesting adherence may exceed 80%.

Market Dynamics: The company sees potential for increased patient referrals due to competitors' marketing efforts, although quantifying this impact is still early.

Combination Therapy Potential: Interest in combining Rezdiffra with other mechanisms, including GLP-1s, is being explored, with a focus on enhancing efficacy and tolerability.

Long-Term Leadership: Management emphasized a long-term strategy to maintain leadership in the MASH market, with a focus on building a sustainable pipeline and addressing the needs of a complex disease landscape. Overall, Madrigal Pharmaceuticals reported a strong quarter with significant growth in sales and patient adoption of Rezdiffra, while also outlining strategic initiatives for future growth and addressing potential competitive pressures and market challenges.